A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
about
The role of pembrolizumab in the treatment of advanced non-small cell lung cancerA Metabolic Immune Checkpoint: Adenosine in Tumor MicroenvironmentCancer immunotherapy: the beginning of the end of cancer?The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA GuidelinesMelanoma: oncogenic drivers and the immune systemNarrowing the Gap: Preserving Repertoire Diversity Despite Clonal Selection during the CD4 T Cell ResponsePembrolizumabNivolumab in the treatment of malignant melanoma: review of the literatureMolecular and cellular insights into T cell exhaustionRegulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological DisordersHigh-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint TracersAllosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesStructural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumabHuman NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 ReceptorEmerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasisFeatures of Memory-Like and PD-1(+) Human NK Cell SubsetsCross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentNovel therapeutic strategies for multiple myelomaPD-1 and PD-L1 antibodies for melanomaAcute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor FunctionT cell exclusion, immune privilege, and the tumor microenvironmentStructural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapyPD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma ViremiaSorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpointNivolumab and ipilimumab versus ipilimumab in untreated melanomaSequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine.Restoring the balance: immunotherapeutic combinations for autoimmune diseaseIpilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush.Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.Decreased T helper 17 cells in tuberculosis is associated with increased percentages of programmed death ligand 1, T helper 2 and regulatory T cells.Extracellular adenosine-mediated modulation of regulatory T cells.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Adaptor protein DOK3 promotes plasma cell differentiation by regulating the expression of programmed cell death 1 ligands.PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease.Unique human immune signature of Ebola virus disease in Guinea.PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
P2860
Q26744076-6929280C-6650-47B3-9D4A-B152A29C1C6CQ26749571-AA2C4F3E-C763-4C0A-AD17-856EC8ED560DQ26752277-5D312B57-7255-4E87-81FD-D1D50E69DE3CQ26764792-6A8E36A0-A21D-4360-8E99-28AF74F08CA4Q26775598-0E188C0A-3A0A-41BA-8491-9ED89648E938Q26796086-05607225-7A96-435E-9AF8-0EDCEC573B91Q26796435-6A98BAE4-C349-4664-BA52-39CCB4F6CAAFQ26798330-CC65BBE4-388B-4987-8DC4-0730620AE82EQ26800047-31049C7E-8653-40E2-8638-37603899E6CBQ26997105-FF27278F-5F5B-47B5-9FAF-7E7821C01231Q27300777-1AA8342A-7E92-4B64-A8AE-DEA78256551FQ27644421-F76DD1F4-1574-40E8-85D3-18730B6836D6Q27712488-5A808B40-2634-416C-B0B2-37EAA2139C8CQ28067468-0258C565-7DA7-4AC6-B2A7-53391C67A79FQ28069422-622C5025-17FC-41A2-B841-4EC9E0256FF9Q28073988-7AA3BD34-45BD-4A2E-93E0-89B212E7820AQ28076294-EB81E476-C85D-4538-BDAA-E3AD732A298FQ28081590-27DEB5FD-C947-4218-9263-40D656B3A3FEQ28081882-A3E824C3-E617-43F2-A0AF-10D876D9D2EDQ28109688-514D02EA-4F6E-4462-820C-7AB5C46725B5Q28259872-05DC127C-793C-4412-8B65-C9A84972987BQ28314934-EA2667BB-6D75-424A-95D3-89CBF137B8CEQ28551329-025C46F4-71AA-44C1-8911-82C588A6EA03Q28816970-8A8015AB-1662-4F9B-89B5-30FEF1440882Q29620657-E196C429-1C15-4F5D-8F48-0BE134EE3F89Q30276649-53BF03BB-CD98-4780-BC98-65B6C48389EFQ30638240-90C0859C-1156-44FA-A441-2C911BC59114Q33555986-32C34679-6639-40C4-B3BE-4922777C7994Q33591598-98E91AFC-151C-48CD-9D60-C131F3B4BE6CQ33645224-C384555B-20D2-4976-BD9A-59A6C6D82B06Q33651093-8E546BBA-F983-45A6-99EE-CDC4BD31B332Q33731047-342384DD-0C45-41BE-8424-B26B57D2BA10Q33836905-4AE47FAA-15BC-4D80-8568-AC79ED01AAC8Q33878542-DA1946AB-D8EC-495B-AE2F-9301F6D3844CQ33912075-A936B108-B127-45C7-99E0-6C69F6D75562Q34025469-F111D920-F16D-4B16-B985-835AFA8EF31DQ34509539-7471A80C-1532-4954-B613-0F4B79EC37F2Q34525050-D550202F-5424-45FC-B1B2-5EC05DBDBEAAQ34550012-A0D2A766-6159-415E-BF67-B006384C24DCQ34552791-9F627989-5026-422D-AF81-32ADE4182AAF
P2860
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A rheostat for immune response ...... ages for clinical application.
@en
type
label
A rheostat for immune response ...... ages for clinical application.
@en
prefLabel
A rheostat for immune response ...... ages for clinical application.
@en
P2093
P2860
P356
P1433
P1476
A rheostat for immune response ...... ages for clinical application.
@en
P2093
Shunsuke Chikuma
Sidonia Fagarasan
Taku Okazaki
Yoshiko Iwai
P2860
P304
P356
10.1038/NI.2762
P407
P50
P577
2013-12-01T00:00:00Z